Tabulated list of adverse reactions: The table as follows reflects the data obtained with bendamustine hydrochloride. (See table.)

Description of selected adverse reactions: There have been isolated reports of necrosis after accidental extra-vascular administration and tumour lysis syndrome, and anaphylaxis.
The risk of myelodysplastic syndrome and acute myeloid leukaemias is increased in patients treated with alkylating agents (including bendamustine). The secondary malignancy may develop several years after chemotherapy has been discontinued.
View ADR Reporting Link